Craig C. Estwick
Voorzitter bij Nexpep Pty Ltd.
Profiel
Craig C.
Estwick currently works at Nexpep Pty Ltd., as Chairman from 2009.
Mr. Estwick also formerly worked at ImmusanT, Inc., as Director and Deloitte Consulting Pty Ltd., as Partner in 2000.
Mr. Estwick received his graduate degree in 2003 from The University of Queensland.
Actieve functies van Craig C. Estwick
| Bedrijven | Functie | Begin |
|---|---|---|
| Nexpep Pty Ltd. | Voorzitter | 01-01-2009 |
Eerdere bekende functies van Craig C. Estwick
| Bedrijven | Functie | Einde |
|---|---|---|
Deloitte Consulting Pty Ltd.
 Deloitte Consulting Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Consulting Pty Ltd. provides cyber security consulting services. The company is based in Sydney, Australia. | Corporate Officer/Principal | 01-01-2000 |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Directeur/Bestuurslid | - |
Opleiding van Craig C. Estwick
| The University of Queensland | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
| Nexpep Pty Ltd. | |
Deloitte Consulting Pty Ltd.
Deloitte Consulting Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Consulting Pty Ltd. provides cyber security consulting services. The company is based in Sydney, Australia. | Commercial Services |
